High-Potential Stocks Under $5 to Watch in 2026
AI Podcast
Speculative stocks under $5 present both risk and reward. Despite a challenging small-cap market, an improving economy by 2026 could spur investment. Grab Holdings, a Singaporean super app, shows promise with revenue growth and first-time profitability, though policy risks remain. Vaxart, a clinical-stage biotech, offers high-risk, high-reward potential via needle-free vaccine technology, evidenced by strong buyer dollar flow. ThredUp, a resale platform, demonstrates consistent revenue growth and benefits from the expanding secondhand market, with significant institutional ownership. These companies offer potential upside if execution is sound and market conditions improve.
TradingKey - While there seems to be a trend of investors moving away from speculative penny stocks, there are still many investors who are more inclined to take the risk and see the possible rewards of holding these types of stocks.
Speculative penny stocks are associated with greater risks since many of the companies in this price range do not generate profits and, in some cases, do not generate meaningful revenue.
Additionally, the vast majority of speculative penny stocks are considered small-cap stocks, and as the small-cap sector of the stock market has been beaten down for several years, there is not a lot of strength currently within the Russell 2000.
An improving economic backdrop could be the catalyst for speculative stocks to return to favor by the end of 2026, and these stocks may see new capital injections into the sector.
Given that quality companies will be more important than ever in the future, one way to evaluate a company's quality is by looking at analyst sentiments. Naming companies below will provide a buy recommendation as a result of their constructive outlooks for at least the next 5 years (depending on individual investor risk tolerance and potential upside potential).
Grab Holdings: Opportunities in Emerging Markets
Emerging markets are expected to be winners in 2026, but Grab Holdings (GRAB) hasn't yet benefited from this market narrative.
The Singapore-based super app—part technology platform, part e-commerce hub, part fintech—has fallen almost 26% year to date.
The decline has a backstory: Grab is attempting to merge with Indonesian ride-sharing competitor Go To, which is still in process and could be impacted by legislative changes in Indonesia that would limit its ability to grow in that market.
The most recent earnings results were mixed. Q4 2025 revenues missed estimates by a small amount; however, revenue grew 19% year-over-year, which is more important than the miss on the top line, and the company has posted a profitable year for the first time in its history.
Analysts are estimating that Grab will see profits increase by approximately 120% over the next twelve months, and therefore, they remain bullish on the long-term potential of the stock, assuming the company can mitigate policy risks and the emerging markets overall continue to perform well.
Vaxart: High-Risk Biotech with Vaccine Potential
When we consider penny stocks, biotech usually consists of the balancing act between biotechnology companies, and one company that falls squarely in the "penny stock" category is Vaxart (VXRT), as it trades currently just a little over $0.60 cents per share.
Clinical Stage Biotech has received limited coverage, but Vaxart is still pre-revenue and is developing its drug candidates only at the trial stage.
Some investors feel that Vaxart's platform could greatly expand the types of immune response (and the corresponding protection against infectious diseases), and that much of the income from vaccine sales could come from the increased demand for needle-free vaccines.
Vaxart is developing vaccines for several types of viruses and has designed its platforms to be convenient, needle-free, and produce an inoculation that could produce a larger immune response to the virus.
Although institutional ownership of Vaxart shares is about 18 percent, the dollar flow into Vaxart (the amount of dollars flowing into Vaxart from buyers versus sellers) is remarkable in that the amount of dollars flowing into Vaxart from buyers is nearly 10 times the amount of dollars flowing out of Vaxart to sellers.
For investors who are willing to take the risk of investing in clinical-stage biotechnology stocks in exchange for an upside potential of investing in vaccine platforms, Vaxart is one of the few under-5-dollar stocks that could see significant price movement based on data and partnership announcement catalysts.
ThredUp: Resale Market Growth and Stock Volatility
ThredUp (TDUP) has experienced a lot of ups and downs. Currently down about 43% in 2021, but if measured over a twelve-month period, their share price is up by 44%.
With so much punishment being handed out to unprofitable companies in this market, one would normally expect this decline to be representative of what they have lost as a company rather than an anomaly to their true value.
ThredUp continues growing in popularity with Gen Z. As of the last quarter, their revenue grew 12.5%, year over year, with revenue growth remaining consistent due to sustained demand from consumers.
Supporting the current growth of ThredUp is their ability to refer to the 2025 GlobalData Market Survey and demonstrate that the gross merchandise value (GMV) of secondhand goods will grow 9% annually through 2029.
Additionally, ownership trends indicate 89% of ThredUp's stock is owned by institutional investors, with institutions buying more than double what they are selling on a dollar basis and three times as many participants buying as participants selling.
Furthermore, ThredUp has approximately 17% short interest and is subject to short-term increases in stock price volatility as they continue to benefit from long-term tailwinds associated with increasing acceptance by consumers of resale.
The Future of Speculative Stocks Under $5
Small caps have lagged, and not every sign of life in the Russell 2000 will translate across the category.
Should the economy continue to rebound through 2026, we may see more of a shift back to some selective speculative concepts.
For those investors who want to invest in stocks priced under $5, Grab Holdings, Vaxart, and ThredUp each represent an opportunity for an investor to establish a large ownership position for minimal capital risk and will have the ability to realize upside when execution is done correctly over the next 5 years, and macro conditions improve.
